•A Candidaco-infection can be either primary- or secondarily acquired, i.e., presented together with or following the onset of COVID-19 disease (super-infection).•Immunosuppressants, such as corticosteroids and anti-IL-6 agents, predispose to fungal overgrowth and translocation from the gastrointestinal tract to the bloodstream.•Critically ill COVID-19 patients often presented altered fecal mycobiomes, enriched with members of the genus Candida.•Candidaspp. from blood followed Gram-negative and Gram-positive bacteria as the most common nosocomial isolates in patients already infected with COVID-19.•It has been reported that hospital-onset candidemia rate significantly increased during the COVID-19 pandemic, however incidence varied significantly between studies.•C. albicansled the isolates in COVID-19 and invasive Candidaco-infection in several reports, while the reported incidence of C. parapsilosis and C.aurisincreased during the pandemic.•The knowledge of Candidaspp. local epidemiology, concerning resistance to antifungal agents, remains crucial for the selection of the empirical antifungal treatment.•During the COVID-19 pandemic, an increase in the frequency of resistance to fluconazole have been reported.•The first-line treatment consists of intravenous administration of fluconazole (unless there is local-resistance to fluconazole or suspicion for C. auris) or an echinocandin.•C. aurisis a troublesome pathogen as it can persist in the hospital environment and has modes of transmission like multidrug resistant bacteria. The treatment of C. aurisis challenging, as it may present resistance to several (or even all) major antifungal classes, i.e., polyenes, azoles, and echinocandins.•Invasive Candidaon critically ill patients with COVID-19, increasing morbidity and mortality. Proper awareness and prevention efforts might decrease their incidence and improve their prognosis.